SCHEMBL3661666

SCHEMBL3661666

C#Cc1cncc(-c2cc(NC3CC3)nc(-c3ccccn3)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR39 O43194 4/20 0.45
TYRO3 Q06418 7/20 0.42
MERTK Q12866 7/20 0.42
FLT3 P36888 6/20 0.42
GAS6 Q14393 6/20 0.42
GRM5 P41594 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
CYP2A6 P11509 1/20 0.36
MAPK14 Q16539 1/20 0.36
CSNK2A2 P19784 1/20 0.35
CCNT1 O60563 1/20 0.35
ABL1 P00519 1/20 0.35
CCR6 P51684 1/20 0.35
AXL P30530 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4185251 0.86 GPR39 (0.44) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL3665002 0.84 GPR39 (0.47) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL3664859 0.80 GPR39 (0.51) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL3663909 0.80 GPR39 (0.54) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL3663705 0.79 GPR39 (0.43) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL4192009 0.79 GPR39 (0.43) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL3662150 0.79 DYRK1A (0.41) GPR39TYRO3MERTKGRM5AXL
SCHEMBL3720880 0.78 GPR39 (0.38) GPR39TYRO3MERTKFLT3GAS6
SCHEMBL4175691 0.78 CYP1A2 (0.46) GPR39GRM5ADORA2BADORA1CCNT1
SCHEMBL3714748 0.76 TGFBR1 (0.46) GPR39

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK GPR39 222/4885TYRO3 3492/4885MERTK 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.